

**RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2025**

*(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)*

1.	For the quarter ended	June 30, 2025					
2.	ISIN	INE03QK01018					
3.	Face Value	Re. 1.00/- each					
4.	Name of the Company	Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited)					
5.	Registered Office Address	# 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, ChakalaMidc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999					
6.	Correspondence Address	# 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India					
7.	Telephone & Fax No.	Ph: 040 – 23549414/3311					
8.	Email Address	<a href="mailto:investorservices@suvenpharm.com">investorservices@suvenpharm.com</a>					
9.	Names of the Stock exchanges where the Company’s Securities are listed.	BSE Limited National Stock Exchange of India Ltd					
		Number of shares		% of Total Issued Capital			
10.	Issued Capital	38,25,67,140		100.00%			
11.	Listed Capital (exchange wise) (as per Company Records)	38,25,67,140–NSE 38,25,67,140–BSE		100.00% 100.00%			
12.	Held in dematerialized form in CDSL	1,30,26,024		3.40%			
13.	Held in dematerialized form in NSDL	36,91,68,545		96.50%			
14.	Physical	3,72,571		0.10%			
15.	Total No. of shares (12+13+14)	38,25,67,140		100.00%			
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)			NIL			
17.	Certifying the details of changes in sharecapital during the quarter under consideration as per Table Below						
Particulars*		No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
Allotment of Equity Shares pursuant to the Scheme of Amalgamation		12,80,02,184	Listed	NSE & BSE	Yes	Yes	No

*\*Rights, Bonus, Pref. Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital reduction, forfeiture, any other (Specify)*  
**Note:** Listing approvals were received on May 16, 2025 and Trading approvals were received on May 23, 2025, from NSE and BSE for the above mentioned equity shares allotted pursuant to the scheme of amalgamation

18.	Register of members electronically updated (Y/N)			Yes
19.	Reference of previous quarter with regards to excess dematerialized shares, if any			Nil
20.	Has the Company resolved the matter mentioned in point No. 19 above in the current quarter? If not, reason, why?			Not applicable
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with reasons for delay.			Nil
Total No. of dematrequests		No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days		Nil	Nil	Nil
Pending for more than 21 days		Nil	Nil	Nil
22.	Name, Telephone & Fax No. of Compliance Officer of the Company		Kundan Kumar Jha Ph: 040 – 23549414/3311	
23.	Name, Address, Tel. & Fax No., Reg. No. of Auditor of the Company		CS. D. Renuka Practicing Company Secretary Plot No. 143, Flat No. 301, S V Kausalya Complex, Rajeev Nagar, Hyderabad - 500045 Mobile: +91-98480 59315 Reg. No: ACS11963	
24.	Appointment of Common agency for share registry work, if yes (name and address)		KFin Technologies Limited Selenium Tower B, Plot 31-32 Gachibowli, Financial District Nanakramguda, Hyderabad – 500032	
25.	Any other detail that the auditor may like to provide (e.g. BIFR Company, delisting from S.E, Company changed its name etc.)		NIL	

Durbha  
Renuka

**D. RENUKA**

Company Secretary in Practice

C. P. No. 3460

ICSI Peer Review UIN: L2000TL172900

UDIN: A011963G000797506

Place: Hyderabad

Date: 17/07/2025